<DOC>
	<DOCNO>NCT00515385</DOCNO>
	<brief_summary>The primary purpose phase 1 , double-blind , cohort study evaluate safety , tolerability , pharmacokinetics escalate dos MGAWN1 administer single intravenous ( IV ) infusion healthy adult . Subjects enrol sequentially one 5 dose-level cohort , 8 subject cohort . Six subject cohort receive MGAWN1 ( Neutralizing , Humanized , Monoclonal Antibody ( IgG1k ) West Nile Virus ) 2 receive saline control .</brief_summary>
	<brief_title>A Trial Evaluate Safety Single Intravenous Infusion MGAWN1 Healthy Adults</brief_title>
	<detailed_description />
	<criteria>1 . Written inform consent obtain subject include consent use researchrelated health information , performance studyrelated procedure include screen procedure 2 . Healthy adult male female subject age 1865 year , body mass index ( BMI ) 1832 kg/m2 3 . Subjects must physically healthy determine investigator base medical history , physical examination , ECG , clinical laboratory test within laboratory normal range . To consider normal , following result must pertain : The serum potassium must within normal limit . Hemoglobin must ≥12 mg/dl ; ANC must 1,500upper limit normal ( ULN ) ; platelet must 130,000500,000 μL ; sodium must 130150 moles/L . Each test must exceed upper limit normal : WBC , creatinine , ( provide asymptomatic ) fast blood glucose . Bilirubin must ≤ 2x ULN , ALT ≤ 1.25x ULN , AST ≤1.25x ULN Urinalysis : glucose negative protein ≤ 20 mg/dl . 4 . Have adequate venous access 5 . Have negative assay human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBsAg ) hepatitis C virus ( HCV ) 6 . Women childbearing potential breastfeeding negative serum pregnancy test within 21 day study drug administration well Study Day −1 7 . Women childbearing potential ( include perimenopausal woman menstrual period within 1 year enrollment ) must use appropriate birth control ( define method low failure rate , i.e. , less 1 % per year , use consistently correctly implant , injectables , intrauterine contraceptive device , sexual abstinence , vasectomized partner ) entire duration study participation . Use contraceptive medication allow study . Women undergone total hysterectomy postmenopausal eligible . 8 . In opinion investigator , subject capable understanding comply protocol 9 . Subject nonsmoker , i.e. , refrain tobacco usage , include smokeless tobacco , nicotine patch , etc . 6 month study entry 10 . Subject 's normal alcohol consumption exceed 3 unit per day male exceed 2 unit per day female . Both male female subject permit consume 2 unit alcohol per day throughout study . ( One unit alcohol equivalent 1 ounce hard liquor , 4 ounce wine , 12 ounce beer . ) 11 . Willing forego form experimental treatment study 1 . Subject unwilling unable comply protocol study period cooperate fully investigator site personnel 2 . Subject significant organ abnormality disease 3 . Subject consider scheduled surgical procedure duration study 4 . Subject active malignancy history solid , metastatic , hematologic malignancy exception basal squamous cell carcinoma skin remove 5 . Subject donate lost unit blood within 30 day screen 6 . Subject positive qualitative urine drug test screen abnormal blood alcohol test ( ≥ 10mg/dL ) Study Day −1 7 . Subject receive investigational drug investigational biologically derive pharmaceutical agent within 60 day screen 8 . Subject history seizure , chronic headache , viral encephalitis , clinically significant infection ( include viral ) 14 day dose 9 . Subject receive concomitant medication require prescription , except contraceptive 10 . Use OTC preparation , herbal remedy nutritional supplement ( calcium vitamin D ) within 7 day study drug administration 11 . Subject ongoing drug abuse/dependence ( include alcohol ) ; recent history ( past 5 year ) , treatment , alcohol drug abuse 12 . Subject significant allergy food drug 13 . Currently symptomatic seasonal allergy , history anaphylaxis , asthma , dermatographism eczema 14 . Subject condition ( ) investigator 's opinion would warrant exclusion study prevent subject complete study 15 . Subject unable understand speak and/or write English language certify translation inform consent available</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Randomized</keyword>
	<keyword>Double-Blind</keyword>
	<keyword>Dose-Escalation</keyword>
	<keyword>Cohort Study</keyword>
</DOC>